Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France
ConclusionsMIDO represents a clinically significant advancement in the management of newly diagnosed FLT3-mutated AML. In this analysis, MIDO add-on therapy showed gains in LYs and QALYs versus SOC alone and was found to be a cost-effective option at a €100,000 per QALY threshold for end-of-life treatment.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Economics | European Medicines Agency (EMA) | France Health | Health Management | Leukemia | Stem Cell Therapy | Stem Cells | Transplants